Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Healthy
Interventions: Erdafitinib; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Cancer, Cancer Survivors, Informal Caregivers, Psychological Distress
Interventions: Adaptive Symptom Management and Survivorship Handbook (SMSH) and Telephone Interpersonal Counseling (TIP-C), NCI Brochure; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 555 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer
Interventions: sipuleucel-T, abiraterone acetate; Biological · Drug
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 21
States / cities: La Jolla, California • La Mesa, California • San Diego, California + 14 more

Conditions: Healthy Volunteers
Interventions: AG881 Formulation 1, AG881 Formulation 2, Omeprazole; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Intubation Complication
Interventions: Not listed
Lead sponsor: New York City Health and Hospitals Corporation; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Timeline: 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Lymphoproliferative Disorder, Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Electronic Health Record Review, Follow-Up, Genetic Counseling, Genetic Testing; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more

Conditions: Idiopathic Parkinson's Disease
Interventions: IPX054 200 mg, IPX054 250 mg, CD-LD IR, CD-LD CR, IPX054 200 mg Placebo, IPX054 250 mg Placebo, CD-LD IR Placebo, CD-LD CR Placebo; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Bingham Farms, Michigan • Portland, Oregon

Conditions: Cardiac Failure, Coronary Artery Disease, Sarcoidosis, Amyloidosis, Lupus, Myocarditis, Drug Toxicity
Interventions: Diagnostic Test: Myostrain; Procedure
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Not listed
Enrollment: 19 participants
Timeline: 2019
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Acute Liver Failure, Fulminant Hepatic Failure
Interventions: N-acetylcysteine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 15 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Tai Chi, Exercise; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 23 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pain
Interventions: Suzetrigine; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: Tirzepatide, Single Dose Pen, Multi-use Prefilled Pen; Drug · Device
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: South Miami, Florida • San Antonio, Texas • Salt Lake City, Utah

Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Ovarian Neoplasms
Interventions: RO7515629, tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Denver, Colorado • Nashville, Tennessee

Conditions: Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions: Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection; Drug
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Female Sexual Dysfunction, Female Sexual Dysfunction Due to Physical Condition
Interventions: Transcutaneous electrical nerve stimulation - Tibial Nerve, Transcutaneous electrical nerve stimulation - Genital Nerve, Neutral and Erotic Film Clip Alternation; Device · Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Anger, Aggression
Interventions: Mindfulness Based Stress Reduction, Trauma Recovery Education Class; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Rhinitis, Allergic, Seasonal
Interventions: C-1266-7, C-1266-6 (placebo); Device
Lead sponsor: McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Spinal Cord Injuries, Constipation, Fecal Incontinence, Neurogenic Bowel
Interventions: Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics; Drug · Device
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Metastatic Cancer
Interventions: Genetically Informed Therapy; Genetic
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Healthy Volunteers
Interventions: Brigatinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Schizophrenia
Interventions: ASP6981, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Glendale, California • Austin, Texas

Conditions: Liver Fibroses, Hepatic Steatosis
Interventions: MRI; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: COVID-19
Interventions: IMPROVE; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 1,277 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteers, Overweight, Obesity
Interventions: NNC9204-1177, Cocktail of 5 already approved drugs; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Participants

Symptom Management for Rural-Urban Cancer Survivors and Caregivers

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881

End-tidal Oxygen Can Reliably Predict the Arterial Partial Pressure of Oxygen Among Emergency Department Patients

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

Evaluation of MyoStrain™ in Clinical Practice

Study of N-Acetylcysteine in Acute Liver Failure (ALF)

Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Sublingual vs IV Atropine Bioavailability Study

Effect of Peripheral Neuromodulation on Vaginal Blood Flow - Study 2

Mindfulness for Anger in Veterans With PTSD

Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever

Pharmacokinetics of Neostigmine and Glycopyrrolate

Genetically-informed Therapies for Patients With Metastatic Cancer

A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults

A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

Methods to Detect Liver Fibrosis

COVID-19 Self-testing IMPROVE

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People